Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Inclusion Criteria: * 19 year old ≤ Male or female \< 85 year old * Subject who underwent Endoscopic Submucosal Dissection for Gastric Adenoma or Early Gastric Cancer * Subject who agrees to participate and spontaneously sign the Informed consent form(ICF). Exclusion Criteria: * Known hypersensitivity to any component of ilaprazole * Subjects who are taking contraindicated medications(ex. atazanavir) for experimental and concomitant drug. * Subjects with abnormal levels in the laboratory tests * Total Bilirubin, Creatinine\> 1.5 times upper limit of normal * Alanine transaminase(ALT), Aspartate transaminase(AST), Alkaline phosphatase, Blood urea nitrogen(BUN)\> 2 times upper limit of normal * Subjects diagnosed with other cancer within 5 years other than stomach cancer. * Subjects with a history of Zollinger-Ellison syndrome, Barrett's esophagus, primary esophageal motility abnormality, esophageal strictures, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease * Subjects with a history of major surgery that can affect gastric acid secretion. * Subjects should continue taking the following medicine during the study period : anticholinergics, promoting motility agents, prostaglandin analogs, sucralfate, aspirin, steroid, NSAIDs drug * Subjects with uncontrolled organ failure (liver dysfunction, renal dysfunction) * Pregnant and/or lactating women * Subjects participating in a clinical trial before another trial within 30 days * Inconsistency judged subject by researcher